Publication not explained
This publication has not yet been explained in plain language by the author(s). However, you can still read the publication.
If you are one of the authors, claim this publication so you can create a plain language summary to help more people find, understand and use it.
Read the Original
This page is a summary of: Prognostic and symptomatic benefits with ivabradine: lessons from the SHIFT trial, European Heart Journal Supplements, December 2015, Oxford University Press (OUP), DOI: 10.1093/eurheartj/suv058.
You can read the full text:
Be the first to contribute to this page